Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization
Authors:
- Karen P. AlexanderKAKaren P. Alexander
- Giora WeiszGWGiora Weisz
- Kristi PratherKPKristi Prather
- Stefan JamesSJStefan James
- Daniel B. MarkDMDaniel B. Mark
- Kevin J. AnstromKAKevin J. Anstrom
- Linda Davidson-RayLDLinda Davidson-Ray
- Adam WitkowskiAWAdam Witkowski
- Angel J. MulkayAMAngel J. Mulkay
- Anna OsmukhinaAOAnna Osmukhina
- Ramin Farzaneh-FarRFRamin Farzaneh-Far
- Ori Ben-YehudaOBOri Ben-Yehuda
- 5 January 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 133 (1) , 39-47
Abstract
Background—: Angina often persists or returns in populations following percutaneous coronary intervention (PCI). We hypothesized that ranolazine would be effective in reducing angina and improving quality of life (QOL) in incomplete revascularization (ICR) post-PCI patients. Methods and Results—: In RIVER-PCI, 2604 patients with a history of chronic angina who had ICR post-PCI were randomized 1:1 to oral ranolazine versus placebo; QOL analyses included 2389 randomized subjects. Angina and QOL questionnaires were collected at baseline and months 1, 6, and 12. Ranolazine patients were more likely than placebo to discontinue study drug by month 6 (20.4% versus 14.1%, P P P =0.01) to month 1 (86.6±18.1 versus 85.8±18.5, P =0.27) and month 12 (88.4±17.8 versus 88.5±17.8, P =0.94). SAQ angina frequency repeated measures did not differ in adjusted analysis between groups post baseline (mean difference 1.0; 95% CI -0.2, 2.2; P =0.11). Improvement in SAQ angina frequency was observed with ranolazine at month 6 among diabetics (mean difference 3.3; 95% CI 0.6, 6.1; P =0.02) and those with more angina (baseline SAQ angina frequency ≤60; mean difference 3.4; 95% CI 0.6, 6.2; P =0.02), but was not maintained at month 12. Conclusions—: Despite ICR following PCI, there was no incremental benefit in angina or QOL measures by adding ranolazine in this angiographically-identified population. These measures markedly improved within 1 month of PCI and persisted up to 1 year in both treatment arms. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01442038.Keywords
This publication has 38 references indexed in Scilit:
- Heart Disease and Stroke Statistics—2015 UpdateCirculation, 2015
- Outcomes After Complete Versus Incomplete Revascularization of Patients With Multivessel Coronary Artery DiseaseJACC, 2013
- Cardiovascular Health: The Importance of Measuring Patient-Reported Health StatusCirculation, 2013
- Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX dataEuropean Journal of Cardio-Thoracic Surgery, 2011
- Quality of Life after PCI with Drug-Eluting Stents or Coronary-Artery Bypass SurgeryNew England Journal of Medicine, 2011
- Economic Impact of Angina After an Acute Coronary SyndromeCirculation: Cardiovascular Quality and Outcomes, 2009
- Profile of Chronic and Recurrent Angina Pectoris in a Referral PopulationThe American Journal of Cardiology, 2008
- Effect of PCI on Quality of Life in Patients with Stable Coronary DiseaseNew England Journal of Medicine, 2008
- Disease-Specific Health Status After Stent-Assisted Percutaneous Coronary Intervention and Coronary Artery Bypass SurgeryCirculation, 2003
- Health Status Predicts Long-Term Outcome in Outpatients With Coronary DiseaseCirculation, 2002